FILING ANALYSIS · THURSDAY, OCTOBER 29
ELI LILLY & Co LLY — 8-K: Results of Operations and Financial Condition
positive
Eli Lilly reported a 39% increase in Q3 revenue to $24.4 billion, driven by strong sales of Mounjaro and Zepbound, and raised its full-year revenue guidance to $91.0-92.0 billion. The company also reported a 16% increase in Q3 EPS to $7.22, despite $4.57 of acquired IPR&D charges.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →